DxTerity Diagnostics develops low-cost, transcriptional diagnostics under 21 CFR 11 and ISO 13485 standards. In partnership with Dana Farber Cancer Institute, DxTerity has developed a comprehensive lymphoma classification assay to transform lymphoma care in under-resourced medical communities. DxTerity’s DxDirect testing platform offers speed and cost advantages with its direct-from-sample testing of RNA from tissue or blood.